In Vivo Effects of a Potent, Selective Dppii Inhibitor

UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII
  • Marie-Berthe Maes
  • Anne-Marie Lambeir
  • Pieter Van der Veken
  • Benedicte De Winter
  • Koen Augustyns
  • Simon Scharpé
  • Ingrid De Meester
Part of the Advances in Experimental Medicine and Biology book series (volume 575)


Dipeptidyl Peptidase Disodium Cromoglycate Passive Cutaneous Anaphylaxis Oral Availability DPPIV Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Araki H, Li Y, Yamamoto Y, Haneda M, Nishi K, Kikkawa R and Ohkubo I, 2001, Purification, molecular cloning, and immunohistochemical localization of dipeptidyl peptidase II from the rat kidney and its identity with quiescent cell proline dipeptidase. J. Biochem. (Tokyo) 129: 279–288.Google Scholar
  2. Auget M, Delaflotte S, Chabrier EP and Braquet P, 1989, Comparative effects of endothelin and phorbol 12–13 dibutyrate. Life Sci. 45: 2051–2059.CrossRefGoogle Scholar
  3. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A, 1999, The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem. 6: 311–327.PubMedGoogle Scholar
  4. Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W, 1990, Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther. 252: 1090–1096.PubMedGoogle Scholar
  5. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM, 1972, Definition and antagonism of histamine H2-receptors. Nature 236: 385–390.CrossRefPubMedGoogle Scholar
  6. Blackman JG, Fastier FN, Patel CM, Wong LC, 1956, Assessment of depressor activity and mydriatic activity of hexamethonium analogues. Br J Pharmacol. 11: 282–288.Google Scholar
  7. Bradford, MM, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing he principle of protein-dye binding. Anal Biochem. 72: 248–254.CrossRefPubMedGoogle Scholar
  8. Brandt I, Lambeir AM, Maes MB, Scharpé S, De Meester I, 2005, Peptide substrates of dipeptidyl peptidases, chapter 1 of this bookGoogle Scholar
  9. Cashin CH, Dawson W, Kitchen EA, 1977, The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with ntiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis. J Pharm Pharmacol. 29: 330–336.PubMedGoogle Scholar
  10. Chen G, Bohner B, Ensor CR, 1954, Evaluation of five methods for testing anticonvulsant activities. Proc Soc Exp Biol Med. 87: 334–339.PubMedGoogle Scholar
  11. Chiravuri M, Schmitz T, Underwood R, Yardley K, Dayal, Y and Huber BT, 1999, A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol. 163: 3092–3099.PubMedGoogle Scholar
  12. D’Amour FE and Smith DL, 1941, A method for determining loss of pain sensation. J Pharmacol Exp Ther. 72: 74–79.Google Scholar
  13. Deacon CF, Ahrén B and Holst JJ, 2004, Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig. Drugs 13: 1091–1102.CrossRefPubMedGoogle Scholar
  14. Dejana E, Callioni A, Quintana A, de Gaetano G, 1979, Bleeding time in laboratory animals. II—A comparison of different assay conditions in rats. Thromb Res. 15: 191–197.CrossRefPubMedGoogle Scholar
  15. Dunham NW, Miya TS, 1957, A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc (Baltim). 46: 208–209.CrossRefGoogle Scholar
  16. Eisenhauer DA and McDonald JK, 1986, A novel dipeptidyl peptidase II from the porcine ovary. Purification and characterization of a lysosomal serine protease showing enhanced specificity for prolyl bonds. J Biol Chem. 261: 8859–8865.PubMedGoogle Scholar
  17. Erjavec F, Adamic S, 1965, Cardiotonic and active transport-inhibiting action of some cardiotonic glycosides and ivorine. Arch Int Pharmacodyn Ther. 155: 251–261.PubMedGoogle Scholar
  18. Freundt KJ, 1965, Adrenergic alpha-and beta-receptors in the mouse iris. Nature 206: 725–726.CrossRefPubMedGoogle Scholar
  19. Fukasawa K, Fukasawa KM, Hiraoka BY and Harada M, 1983, Purification and properties of dipeptidyl peptidase II from rat kidney. Biochim Biophys Acta. 745: 6–11.PubMedGoogle Scholar
  20. Ganapathy V, Leibach FH, 1986, Carrier-mediated reabsorption of small peptides in renal proximal tubule. Am J Physiol. 251(6 Pt 2): F945–53.PubMedGoogle Scholar
  21. Gardner CJ, Twissell DJ, Coates J, Strong P, 1994, The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur J Pharmacol. 257: 117–121.CrossRefPubMedGoogle Scholar
  22. Goose J, Blair AM, 1969, Passive cutaneous anaphylaxis in the rat, induced with two homologous reagin-like antibodies and its specific inhibition with disodium cromoglycate. Immunology. 16: 749–760.PubMedGoogle Scholar
  23. Gossrau R and Lojda Z, 1980, Study on dipeptidylpeptidase II (DPP II). Histochemistry. 70: 53–76.CrossRefPubMedGoogle Scholar
  24. Gossrau R, 1983, Peptide and protein handling by proteases in the kidney of laboratory rodents. Acta Histochem Suppl. 28: 285–293.PubMedGoogle Scholar
  25. Gossrau R, 1991, Histochemical and biochemical studies of dipeptidyl peptidase I (DPP I) in laboratory rodents. Acta Histochem. 91: 85–100.PubMedGoogle Scholar
  26. Groneberg DA, Doring F, Nickolaus M, Daniel H, Fischer A, 2002, Renal assimilation of short chain peptides: visualization of tubular peptide uptake. Pharm Res. 19: 1209–1214.CrossRefPubMedGoogle Scholar
  27. Gylys JA, Muccia PM, Taylor MK, 1963, Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antidepressant. Ann N Y Acad Sci. 107: 899–913.PubMedGoogle Scholar
  28. Hagiwara M, Watanabe H, Kawata K, Watanabe K, 1984, A novel method of measurement of gastric acid secretion in intact and conscious rats. Yakugaku Zasshi. 104: 1090–1094.PubMedGoogle Scholar
  29. Hamilton TC, Weir SW, Weston AH, 1986, Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol. 88: 103–111.PubMedGoogle Scholar
  30. Hirotsu I, Kihara T, Hattori Y, Hatta M, Hirose N, Ishihara T, Satoh F, 1988, General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs. Arzneimittelforschung 38: 1410–1417.PubMedGoogle Scholar
  31. Ho RS, Aranda CG, 1979, The influence of 2,2-dimethyl-1-(4-methylphenyl)-1-propanone (SaH 50-283) on food efficiency in rats. Arch Int Pharmacodyn Ther. 237: 98–109.PubMedGoogle Scholar
  32. Hopsu-Havu VK, Jansen CT and Jarvinen M, 1970, Partial purification and characterization of an acid dipeptide naphthylamidase (carboxytripeptidase) of the rat skin. Arch Klin Exp Dermatol. 236: 282–296.CrossRefPubMedGoogle Scholar
  33. Irwin S., 1968, Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222–257.CrossRefPubMedGoogle Scholar
  34. Jiaang WT, Chen YS, Hsu T, Wu SH, Chien CH, Chang CN, Chang SP, Lee SJ, Chen X, 2005, Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 15: 687–691.CrossRefPubMedGoogle Scholar
  35. Lambeir AM, Durinx C, Scharpe S, De Meester I, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40: 209–294.PubMedGoogle Scholar
  36. Lankas G, Leiting B, Roy RS, Eiermann G, Biftu T, Kim D, Ok H, Weber A and Thornberry NA, 2004, Inhibition of DPP8/9 results in toxicity in preclinical species: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of Type 2 DM. Diabetes (suppl. 2); 53: A2, 7-OR (Abstract)Google Scholar
  37. Lee CH, Strosberg AM, Roszkowski AP, Warren LA, 1982, A model for evaluation of postural hypotension induced by drugs in conscious restrained normotensive rats. J Pharmacol Methods. 7: 15–24.CrossRefPubMedGoogle Scholar
  38. Leibowitz M, Gordon RJ, Wolf PS, Sonnino-Goldman P, 1984, In vivo anti-allergic and Bronchopulmonary pharmacology of REV 3164 in rats and guinea-pigs. Arch Int Pharmacodyn Ther. 271: 135–154.PubMedGoogle Scholar
  39. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT and Thornberry NA, 2003, Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J. 371: 525–532.CrossRefPubMedGoogle Scholar
  40. Lippmann W, Pugsley TA, 1977, Effects of 3,4-dihydro-lH-1,4-oxazino[4,3-a] indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities. Arch Int Pharmacodyn Ther. 227: 324–342.PubMedGoogle Scholar
  41. Lipschitz WL, Hadidian Z and Kerpcsar A, 1943, Bioassay of diuretics. J Pharmacol Exper Ther. 79: 97–110.Google Scholar
  42. Lotti VJ, Cerino DJ, Kling PJ, Change RS, 1986, A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sci. 39: 1631–1638.CrossRefPubMedGoogle Scholar
  43. Lotti VJ, Chang RS, 1989, A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol. 162: 273–280.CrossRefPubMedGoogle Scholar
  44. Lynn KR, 1991, The isolation and some properties of dipeptidyl peptidases II and III from porcine spleen. Int J Biochem. 23: 47–50.CrossRefPubMedGoogle Scholar
  45. Maes MB, Lambeir AM, Gilany K, Senten K, Van der Veken P, Leiting B, Augustyns K, Scharpé S, De Meester I, 2005, Kinetic investigation of human dipeptidyl peptidase II mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase/dipeptidyl peptidase 7. Biochem J. 386: 315–324.CrossRefPubMedGoogle Scholar
  46. McDonald JK, Reilly TJ, Zeitman BB and Ellis S, 1968, Dipeptidyl arylamidase II of the pituitary. Properties of lysylalanyl-beta-naphthylamide hydrolysis: inhibition by cations, distribution in tissues, and subcellular localization. J Biol Chem. 243: 2028–2037.PubMedGoogle Scholar
  47. McDonald JK, Leibach FH, GrindelandREand Ellis S, 1968, Purification of dipeptidyl aminopeptidase II (dipeptidyl arylamidase II) of the anterior pituitary gland. Peptidase and dipeptide esterase activities. J Biol Chem. 243: 4143–4150.PubMedGoogle Scholar
  48. McDonald JK and Schwabe C, 1980, Dipeptidyl peptidase II of bovine dental pulp. Initial demonstration and characterization as a fibroblastic, lysosomal peptidase of the serine class active on collagen-related peptides. Biochim Biophys Acta. 616: 68–81.PubMedGoogle Scholar
  49. McIntyre JA and Castaner J, 2004, Talabostat. Oncolytic, hematopoietic agent, dipeptidyl-peptidase IV (CD26) inhibitor, fibroblast activation protein inhibitor. Drugs of the Future 29: 882–886.CrossRefGoogle Scholar
  50. Mentlein R and Struckhoff G, 1989, Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 52: 1284–1293.CrossRefPubMedGoogle Scholar
  51. Mentlein R, 1999, Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 85: 9–24.CrossRefPubMedGoogle Scholar
  52. Neuworth MB, Louter RJ, Barnhart JW, Sefranka JA, McIntosh DD, 1970, Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols. J Med Chem. 13: 722–729.CrossRefPubMedGoogle Scholar
  53. Nwangwu PU, Holcslaw TL, Stohs SJ, 1977, A rapid in vivo technique for preliminary screening of antiarrhythmic agents in mice. Arch Int Pharmacodyn Ther. 229: 219–226.PubMedGoogle Scholar
  54. Omosu M, Komine I, Becker RH, Scholkens BA, 1988, General pharmacology of ramipril. Arzneimittelforschung 38: 1309–1317.PubMedGoogle Scholar
  55. Paton WD, Zar MA, 1968, The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol. 194: 13–33.PubMedGoogle Scholar
  56. Protais P, Costentin J, Schwartz JC, 1976, Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl) 50: 1–6.CrossRefGoogle Scholar
  57. Robert A, Nezamis JE, Lancaster C, Hanchar AJ, 1979, Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77: 433–43.PubMedGoogle Scholar
  58. Root MA, Sigal MV Jr, Anderson RC, 1959, Pharmacology of 1-(p-chlorobenzenesulfonyl)-3-n-propylurea (chlorpropamide). Diabetes. 8: 7–13.PubMedGoogle Scholar
  59. Rosenblum JS, Kozarich JW, 2003, Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 7: 496–504.CrossRefPubMedGoogle Scholar
  60. Saxena PR, Lawang A, 1985, A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn Ther. 277: 235–252.PubMedGoogle Scholar
  61. Schurr PE, Schultz JR, Day CE, 1976, High volume screening procedures for hypobetalipoproteinemic activity in rats. Adv Exp Med Biol. 67(00): 215–229.PubMedGoogle Scholar
  62. Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta. 1550: 107–116.PubMedGoogle Scholar
  63. Sentandreu MA and Toldrá F, 2001, Partial purification and characterisation of dipeptidyl peptidase II from porcine skeletal muscle. Meat Science 57: 93–103.CrossRefGoogle Scholar
  64. Senten K, Van der Veken P, Bal G, De Meester I, Lambeir AM, Scharpé S, Bauvois B, Haemers A, Augustyns K, 2002, Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 12: 2825–2828.CrossRefPubMedGoogle Scholar
  65. Senten K, Van Der Veken P, De Meester I, Lambeir AM, Scharpé S, Haemers A, Augustyns K, 2004, Gamma-amino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J Med Chem. 47: 2906–2916.CrossRefPubMedGoogle Scholar
  66. Siegmund E, Cadmus R, Lu G, 1957, A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med. 95: 729–731.PubMedGoogle Scholar
  67. Sippel H, Estler CJ, 1990, Comparative evaluation of hepatotoxic side effects of various newtrypanocidal diamidines in rat hepatocytes and mice. Arzneimittelforschung. 40: 290–293.PubMedGoogle Scholar
  68. Trolin G, 1975, Effects of pentobarbitone and decerebration on the clonidine-induced circulatory changes. Eur J Pharmacol. 34: 1–7.CrossRefPubMedGoogle Scholar
  69. Turner R, 1965, Depressants of the central nervous system in Screening methods in pharmacology, volume I, pp. 69–86, Academic Press, New York.Google Scholar
  70. Underwood R, Chiravuri M, Lee H, Schmitz T, Kabcenell AK, Yardley K and Huber BT, 1999, Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem. 274: 34053–34058.CrossRefPubMedGoogle Scholar
  71. Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpé S, 1995, Proline motifs in peptides and their biological processing. FASEB J. 9:736–744.PubMedGoogle Scholar
  72. Wasserman MA, Griffin RL, 1977, Thromboxane B2-comparative bronchoactivity in experimental systems. Eur J Pharmacol. 46: 303–313.CrossRefPubMedGoogle Scholar
  73. Wilson C, Buckingham RE, Mootoo S, Parrott LS, Hamilton TC, Pratt SC and Cawthorne MA, 1988, In vivo and in vitro studies of cromokalim (BRL 34915) and glibenclamide in the rat. Br J Pharmacol. 93: 126p.Google Scholar
  74. Winter CA, Risley EA, Nuss GW, 1962, Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 111: 544–547.PubMedGoogle Scholar
  75. Yen TT, Pearson DV, Powell CE, Kirschner GL, 1978, Thermal stress elevates the systolicGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Marie-Berthe Maes
    • 1
  • Anne-Marie Lambeir
    • 1
  • Pieter Van der Veken
    • 2
  • Benedicte De Winter
    • 3
  • Koen Augustyns
    • 2
  • Simon Scharpé
    • 1
  • Ingrid De Meester
    • 1
  1. 1.Laboratory for Medical BiochemistryUniversity of AntwerpWilrijkBelgium
  2. 2.Laboratory for Medicinal Chemistry, Department of Pharmaceutical SciencesUniversity of AntwerpWilrijkBelgium
  3. 3.Division of Gastroenterology, Faculty of MedicineUniversity of AntwerpWilrijkBelgium

Personalised recommendations